Delphia (Usa) Inc. Vertex Pharmaceuticals Inc Transaction History

Delphia (Usa) Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $148,091 - $165,749	-471 Reduced 31.57%	1,021 $359,000
Q1 2023 May 15, 2023	BUY	$283.23 - $323.1 $214,405 - $244,586	757 Added 102.99%	1,492 $470,000
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $210,033 - $236,287	735 New	735 $212,000
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $96,568 - $120,238	-411 Reduced 19.78%	1,667 $470,000
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $1,549 - $1,826	7 Added 0.34%	2,078 $542,000
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $366,587 - $462,764	2,071 New	2,071 $455,000

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $120B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Delphia (Usa) Inc., based on Form 13F filings with the SEC.

Stay updated on Delphia (Usa) Inc. with notifications on news.